Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATRA |
---|---|---|
09:32 ET | 28203 | 0.6 |
09:34 ET | 100 | 0.6349 |
09:36 ET | 18273 | 0.61 |
09:38 ET | 2100 | 0.61 |
09:39 ET | 1500 | 0.61 |
09:41 ET | 8401 | 0.6299 |
09:43 ET | 6656 | 0.62005 |
09:45 ET | 7668 | 0.62 |
09:48 ET | 5680 | 0.6298 |
09:50 ET | 6057 | 0.6269 |
09:52 ET | 10925 | 0.6176 |
09:54 ET | 5670 | 0.6299 |
09:56 ET | 2600 | 0.63 |
09:57 ET | 118 | 0.6301 |
09:59 ET | 527 | 0.6219 |
10:01 ET | 1763 | 0.623 |
10:03 ET | 4693 | 0.6138 |
10:06 ET | 7781 | 0.6137 |
10:08 ET | 4628 | 0.623 |
10:10 ET | 8404 | 0.623 |
10:12 ET | 6769 | 0.6164 |
10:14 ET | 12354 | 0.6116 |
10:15 ET | 18093 | 0.6094 |
10:17 ET | 17953 | 0.6 |
10:19 ET | 9883 | 0.6001 |
10:21 ET | 3119 | 0.6 |
10:24 ET | 8965 | 0.6011 |
10:28 ET | 5678 | 0.6006 |
10:30 ET | 12498 | 0.6082 |
10:32 ET | 14843 | 0.6091 |
10:33 ET | 4734 | 0.6209 |
10:35 ET | 6318 | 0.623 |
10:37 ET | 4700 | 0.6239 |
10:39 ET | 1600 | 0.618524 |
10:42 ET | 200 | 0.6184 |
10:44 ET | 300 | 0.6185 |
10:46 ET | 200 | 0.6184 |
10:50 ET | 19999 | 0.61 |
10:51 ET | 14853 | 0.6097 |
10:53 ET | 800 | 0.6092 |
10:55 ET | 100 | 0.6091 |
10:57 ET | 700 | 0.6104 |
11:00 ET | 3303 | 0.6092 |
11:02 ET | 6529 | 0.6103 |
11:04 ET | 7757 | 0.6204 |
11:06 ET | 4648 | 0.6252 |
11:08 ET | 4590 | 0.6252 |
11:09 ET | 4940 | 0.627 |
11:11 ET | 1275 | 0.6232 |
11:15 ET | 1725 | 0.629 |
11:18 ET | 6110 | 0.6299 |
11:20 ET | 5826 | 0.6271 |
11:22 ET | 4796 | 0.6273 |
11:24 ET | 6277 | 0.6294 |
11:26 ET | 8715 | 0.6295 |
11:27 ET | 7165 | 0.6294 |
11:29 ET | 9694 | 0.6255 |
11:31 ET | 9593 | 0.6296 |
11:33 ET | 2778 | 0.6318 |
11:36 ET | 1783 | 0.6318 |
11:38 ET | 100 | 0.6314 |
11:40 ET | 991 | 0.6271 |
11:42 ET | 5104 | 0.6229 |
11:44 ET | 200 | 0.6229 |
11:45 ET | 12964 | 0.6252 |
11:47 ET | 25085 | 0.6309 |
11:49 ET | 34400 | 0.6246 |
11:51 ET | 8100 | 0.63 |
11:54 ET | 16556 | 0.63 |
11:56 ET | 1800 | 0.6252 |
11:58 ET | 26846 | 0.63 |
12:00 ET | 3646 | 0.6281 |
12:02 ET | 100 | 0.6281 |
12:03 ET | 5200 | 0.6256 |
12:05 ET | 482 | 0.6256 |
12:07 ET | 600 | 0.6256 |
12:09 ET | 100 | 0.6256 |
12:12 ET | 2450 | 0.6257 |
12:14 ET | 508 | 0.62565 |
12:16 ET | 3350 | 0.6257 |
12:18 ET | 2130 | 0.6233 |
12:20 ET | 1600 | 0.613 |
12:21 ET | 2465 | 0.6033 |
12:23 ET | 10700 | 0.6034 |
12:25 ET | 3264 | 0.6028 |
12:27 ET | 1345 | 0.603099 |
12:30 ET | 4505 | 0.6031 |
12:32 ET | 1000 | 0.6034 |
12:34 ET | 11878 | 0.6043 |
12:36 ET | 1300 | 0.6034 |
12:38 ET | 45015 | 0.6 |
12:39 ET | 3625 | 0.5869 |
12:41 ET | 9568 | 0.587 |
12:43 ET | 200 | 0.5878 |
12:45 ET | 3647 | 0.59185 |
12:48 ET | 5173 | 0.59 |
12:50 ET | 8322 | 0.5883 |
12:52 ET | 4813 | 0.5883 |
12:54 ET | 100 | 0.5883 |
12:56 ET | 8473 | 0.6 |
12:57 ET | 4413 | 0.6095 |
12:59 ET | 4900 | 0.6093 |
01:01 ET | 4600 | 0.6006 |
01:03 ET | 9612 | 0.6095 |
01:06 ET | 6226 | 0.619 |
01:08 ET | 17990 | 0.6102 |
01:10 ET | 10045 | 0.6027 |
01:12 ET | 2098 | 0.6011 |
01:14 ET | 3285 | 0.6011 |
01:17 ET | 988 | 0.6049 |
01:19 ET | 6942 | 0.6052 |
01:21 ET | 6086 | 0.6073 |
01:24 ET | 4334 | 0.614 |
01:26 ET | 5900 | 0.6073 |
01:28 ET | 5534 | 0.60985 |
01:30 ET | 5099 | 0.6112 |
01:32 ET | 5931 | 0.609 |
01:33 ET | 16170 | 0.6073 |
01:35 ET | 7043 | 0.6035 |
01:37 ET | 152 | 0.60345 |
01:42 ET | 2800 | 0.604 |
01:44 ET | 9206 | 0.6069 |
01:46 ET | 4200 | 0.6101 |
01:48 ET | 4669 | 0.6101 |
01:50 ET | 4414 | 0.6189 |
01:51 ET | 12947 | 0.62 |
01:53 ET | 4670 | 0.6193 |
01:55 ET | 4800 | 0.62 |
01:57 ET | 4496 | 0.6189 |
02:00 ET | 4482 | 0.6204 |
02:02 ET | 9617 | 0.62 |
02:04 ET | 3918 | 0.62 |
02:06 ET | 14923 | 0.620001 |
02:08 ET | 211 | 0.62005 |
02:09 ET | 686 | 0.6201 |
02:11 ET | 2505 | 0.6201 |
02:13 ET | 518 | 0.62 |
02:15 ET | 725 | 0.6201 |
02:18 ET | 1215 | 0.62005 |
02:20 ET | 1300 | 0.62005 |
02:22 ET | 6536 | 0.62 |
02:24 ET | 211 | 0.62005 |
02:26 ET | 13434 | 0.6201 |
02:27 ET | 1914 | 0.62005 |
02:29 ET | 100 | 0.62005 |
02:31 ET | 312 | 0.6201 |
02:33 ET | 5400 | 0.62 |
02:36 ET | 1779 | 0.6201 |
02:38 ET | 2228 | 0.62 |
02:40 ET | 5859 | 0.62 |
02:42 ET | 521 | 0.6201 |
02:44 ET | 3200 | 0.62 |
02:45 ET | 500 | 0.62005 |
02:47 ET | 425 | 0.62005 |
02:49 ET | 23976 | 0.62 |
02:54 ET | 230 | 0.62005 |
02:56 ET | 300 | 0.62 |
02:58 ET | 235 | 0.62005 |
03:00 ET | 6102 | 0.62005 |
03:02 ET | 705 | 0.6183 |
03:03 ET | 5753 | 0.6062 |
03:05 ET | 10322 | 0.6038 |
03:07 ET | 200 | 0.6057 |
03:12 ET | 1100 | 0.6037 |
03:14 ET | 200 | 0.6037 |
03:20 ET | 100 | 0.6077 |
03:21 ET | 100 | 0.6077 |
03:23 ET | 100 | 0.6057 |
03:25 ET | 2400 | 0.6037 |
03:27 ET | 600 | 0.6037 |
03:30 ET | 1200 | 0.6037 |
03:32 ET | 21020 | 0.6149 |
03:34 ET | 200 | 0.6103 |
03:39 ET | 10402 | 0.610755 |
03:41 ET | 200 | 0.6135 |
03:43 ET | 100 | 0.6162 |
03:45 ET | 200 | 0.6107 |
03:48 ET | 253 | 0.6103 |
03:50 ET | 400 | 0.6103 |
03:52 ET | 1122 | 0.6101 |
03:54 ET | 637 | 0.6101 |
03:56 ET | 15281 | 0.61 |
03:57 ET | 9750 | 0.6123 |
03:59 ET | 66989 | 0.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atara Biotherapeutics Inc | 73.5M | -0.3x | --- |
Ikena Oncology Inc | 69.0M | -0.9x | --- |
Jaguar Health Inc | 75.8M | -0.2x | --- |
Curis Inc | 69.6M | -1.4x | --- |
LAVA Therapeutics NV | 69.4M | -1.7x | --- |
Collplant Biotechnologies Ltd | 72.6M | -10.0x | --- |
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $73.5M |
---|---|
Revenue (TTM) | $34.7M |
Shares Outstanding | 120.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-2.12 |
Book Value | $-0.93 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -669.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.